In conclusion, the collective downregulation of MHC‐II expression and the alteration of immune‐related soluble factors driven by RECQL4 may promote tumour evasion, potentially impairing the efficacy of ICI therapy in melanoma patients (Figure 8). The gene discussed is RECQL4; the disease is neoplasm.